Earnings

Integra LifeSciences Anticipates Flooding Related Supply Disruption To Impact Q3 Revenue By ~$7M, Q4 Revenue By $15M - $20M; Expects Q3 Revenue Range Of ~$410M - $412M, Adjusted EPS Range $0.55 - $0.59; Updates FY26 Adjusted EPS Range From $2.40 - $2.50 To $2.30 - $2.40, Revenue Range From $1.654B - $1.695B To $1.634B - $1.654B

Oct 2, 2026 · 08:09 AM ET· updated 2h ago

Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today provided certain unaudited preliminary third quarter results and an update to its full-year 2026

Why It Matters

Bad flooding damaged Integra's supply chain and will cut sales this year. When a company loses millions in expected sales, it signals real operational challenges to watch.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

IART13.48

-2.61 (-16.22%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.